Last reviewed · How we verify
V-01
At a glance
| Generic name | V-01 |
|---|---|
| Sponsor | Livzon Pharmaceutical Group Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multicenter Real-World Study of Hyperthermia in Warts of Special Population (NA)
- Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis (NA)
- Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts (NA)
- Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG) (NA)
- Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy (PHASE2)
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (PHASE3)
- Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) (PHASE1)
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V-01 CI brief — competitive landscape report
- V-01 updates RSS · CI watch RSS
- Livzon Pharmaceutical Group Inc. portfolio CI